Effect of I_f Channel Blocker on Symptoms, quality of Life and Effort Tolerance in Patients with Idiopathic Dilated Cardiomyopathy

Thesis

Submitted for Partial Fulfilment of Masters Degree in Cardiology

Mohamed Ahmed Hussien
M.B.B.Ch

Supervised by

Dr. Mohamed Gamal Abd Albarr

Professor of Cardiology

Faculty of Medicine-Ain Shams University

Dr. Mona Mustafa Rayan

Professor of Cardiology

Faculty of Medicine-Ain Shams University

Dr. Zeinab Abd Elsalam fahmy

Assistant professor of Cardiology

Faculty of Medicine-Ain Shams University

Faculty of Medicine Ain Shams University 2011

تأثير استخدام عقار الإيفا برادين على معدل بذل الجهد ومدى كفاءة الحياة رسالة

توطئة للحصول على درجة الماجستير في أمرض القلب

مقدمة من طبيب/ محمد أحمد حسين

تحت إشراف

أ.د/ محمد جمال عبد البر

أستاذ أمر اض القلب والأوعية الدموية كلية الطب جامعة عين شمس

أد/ منى مصطفى ريان أستاذ أمراض القلب والأوعية الدموية كلية الطب جامعة عين شمس

د/ زينب عبد السلام أستاذ مساعد أمراض القلب والأوعية الدموية كلية الطب جامعة عين شمس

کلیــة الطــب جامعــة عین شمـس ۲۰۱۱

Acknowledgment

First and foremost, I thank God for helping and guiding me in accomplishing this work.

I would like to express my sincere gratitude to Prof Dr.

Mohamed Gamal Abd Elbarr, Professor of Cardiology, Ain

Shams University, for his great support, his active guidance and overwhelming kindness throughout this work.

A special tribute to Dr. Mona Mostafa Rayan Professor of Cardiology, Ain Shams University, for her sincere supervision, stimulating views and faithful advice.

I must extend my warmest gratitude to Dr. Zeinab Abd Elsalam Assistant professor of Cardiology, Ain Shams University, for his great help and support to me.

I would be rather ungrateful if I forgot to express my gratitude to Prof Dr. Ayman Saleh and the group of ivabradine prospective study who extended the aid to me in my thesis

Last but definitely not least, I would like to thank my family for their support, patience and encouragement.

Mohamed Hussien

Contents

Title	Page
List of Abbreviations	I
List of Tables	III
List of Figures	V
Introduction	1
Aim of the Study	2
Review of Literature	
Chapter (1): Dilated Cardiomyopathy	3
Chapter (2): Heart Rate Reduction by Ivabradine	35
as a New Therapeutic approach in Heart Failure	
Chapter (3): Quality of Life	48
Chapter (4): Exercise Tolerability	56
Patients and Methods	
Results	
Discussion	
Summary	108
Conclusion	111
Recommendations	112
References	113
Arabic Summary	١

List of Abbreviations

ACC : American College of Cardiology

ACEI : Angiotensin-Converting Enzyme Inhibitor

AHA : American Heart Association

ARB : Angiotensin receptor blocker

ARVC/D: Arrhythmogenic Right Ventricular Cardiomyopathy/

Dysplasia

BB : Beta-blocker

b.i.d : twice daily.

Bpm: beat per minute.

CIBIS II: Cardiac Insufficiency Bisoprolol Study II

CRT : Cardiac Resynchronization Therapy.

DBP : Diastolic blood pressure.

DCM : Dilated CardioMyopathy

DM : Diabetes Mellitus

ECG : Electrocardiogram.

ECHO: Echocardiography.

ESC : European Society of Cardiology

ET : Endothelin.

HF : Heart Failure.

HIV : Human immunodeficiency virus

HR: Heart rate

HRQL : Health related quality of life

HTN: Hypertension

IABP : Intra Aortic Balloon Counterpulsation.

I

ICD : Implantable Cardioverter-Defibrillator.

LVAD : Left Ventricular Assist Device

LVEDD: Left ventricular end-diastolic diameter

LVEDV: Left ventricular end-diastolic volume

LVEF : Left ventricular ejection fraction.

LVESD: Left ventricular end-systolic diameter

LVESV : Left ventricular end-systolic volume

MR : Mitral regurgitation

NE : Norepinephrine.

No. : Number.

NS : Non significant

NYHA: New York Heart Association.

o.d. : once daily.

PASP : Pulmonary artery systolic pressure

PRO : Patient related health outcome

RAS : Renin-angiotensin system.

RV : Right ventricle

SBP : Systolic blood pressure

SD : Standard Deviation.

SV : Stroke Volume.

t.i.d : three times a day.

VAD : Ventricular Assist Device.

VT : Ventricular Tachycardia.

WHO : World Health Organization.

List of Tables 🗷

List of Tables

Table No.	Title	Page
Table (1)	Framingham criteria for diagnosing heart	21
	failure	
Table (2)	ACC/AHA stages of heart failure and	22
	NYHA classification	
Table (3)	Investigation that are indicated in the	23
	management of a case of heart failure	
Table (4)	Demographic criteria and risk factors of	81
	the patients	
Table (5)	BB and ACEI doses taken by the patients	83
Table (6)	Demographic data and risk factor	84
	distribution of both groups at	
	randomization	
Table (7)	Comparison the doses of antifailure	85
	therapy in both groups	
Table (8)	NYHA Class in both subgroups at	85
	randomization	
Table (9)	Blood pressure and heart rate in both	86
	groups at randomization	
Table (10)	Baseline characteristics of the population	87
	study at randomization as regards various	
	echocardiographic parameters	
Table (11)	Exercise tolerance and quality of life in	88
	both subgroups at randomization	

List of Tables &

Table No.	Title	Page
Table (12)	Distribution of patients according to their	89
	NYHA functional classes in each group	
	after 3 months	
Table (13)	Follow up data of blood pressure and	90
	heart rate of both groups	
Table (14)	Echocardiographic parameters of group	93
	(A) at baseline and at 3 months	
Table (15)	Echocardiographic parameters of group	93
	(B) at baseline and at 3 months	
Table (16)	Exercise tolerance in group(A), at	94
	baseline and after 3 months	
Table (17)	Exercise tolerance in group(B), at	94
	baseline and after 3 months	
Table (18)	Comparison between treatment and	95
	placebo groups as regard Minnesota-	
	questionnaire before, after treatment	
Table (19)	Correlations between heart rate and	97
	quality of life and exercise tolerance	
Table (20)	Hospital readmission due to heart failure	99
	in both groups	

List of Figures 🗷

List of Figures

Figure No.	Title	Page
Figure (1)	Risk factor distribution among all	81
	patients	
Figure (2)	Blood pressure changes in both groups at	91
	randomization and after 3 months	
Figure (3)	Heart rate changes in both groups at	91
	randomization and after 3 months	
Figure (4)	Quality of life in both groups before and	95
	after therapy	
Figure (5)	Correlation between NYHA grade and	96
	heart rate	
Figure (6)	Corelation between Heart rate and	98
	quality of life	
Figure (7)	Corelation between Heart rate and	98
	exercise tolerance	

Introduction

Beta-adrenergic receptor blockers (BB) are strongly indicated in patients with myopathic ventricles, however a considerable percentage does not receive BB and this occurs for several reasons including absolute contraindications or intolerance to the recommended doses (*Kannel et al.*, 1987).

The benefits of beta-adrenergic receptor blockers in myopathic ventricles are multifactorial and are partly due to the gradual reduction in heart rate (*Gullestad et al.*, 2001).

The If channel blocker reduces the heart rate selectively without affecting the conduction system nor contractility by inhibiting the cardiac pacemaker f-current (If) (Vilaine et al., 2003).

The If channel blocker has been approved to be effective as a beta-adrenergic receptor blockers alternative in ischemic heart disease without left ventricular dysfunction (*Lars et al.*, 2005).

Data are also available for its use in ischemic heart disease with left ventricular dysfunction. But data for its use in left ventricular dysfunction without ischemic heart disease are still lacking.

Aim of the Study &

Aim of the Study

The aim of the study is to prospectively assess the effect of If channel blocker on symptoms, quality of life and effort tolerance in patients with idiopathic dilated cardiomyopathy.

Dilated Cardiomyopathy

Definitions and Classifications of Cardiomyopathy:Ongoing debate:

The concept of heart muscle diseases has a notable and evolving history. In the mid 1850s chronic myocarditis was the only recognized cause of heart muscle disease (Abelmann et al., 1984).

In 1900, the designation of primary myocardial disease was introduced, and it was not until 1957 that the term cardiomyopathy was used for the first time. Over the subsequent 25 years, a number of definitions for cardiomyopathies were advanced in concert with an increasing awareness and understanding of these diseases. Cardiomyopathies, in the original 1980 WHO classification, were defined only as heart muscle disease of unknown cause reflecting a general lack of information available about causation and basic disease mechanisms (*Bradenburg et al.*, 1980).

The most recent WHO definition in 1995 was diseases of myocardium associated with cardiac dysfunction and included newly recognized arrhythmogenic right ventricular cardiomyopathy/ dysplasia (ARVC/D) and primary restrictive cardiomyopathy for the first time (*Richardson et al.*, 1996).

In 2006, AHA expert consensus panel proposed a novel definition: Cardiomyopathies are a heterogeneous group of diseases of the myocardium associated with mechanical and/or electrical dysfunction that usually (but not invariably) exhibit inappropriate ventricular hypertrophy or dilatation and are due to a variety of causes that frequently are genetic. Cardiomyopathies either are confined to the heart or are part of generalized systemic disorders, often leading to cardiovascular death or progressive heart failure-related disability (Maron et al., 2006).

Within this broad definition, cardiomyopathies usually are associated with failure of myocardial performance, which may be mechanical (e.g, diastolic or systolic dysfunction) or a primary electrical disease prone to life—threatening arrhythmias. Indeed the ion channel opathies (long- QT syndrome [LQTS] and brugada syndrome among others) are primary electrical diseases without gross or histopathological abnormalities in which the functional and structural myocardial abnormalities responsible for arrhythmogenesis are at the molecular level in the cell membrane itself (Maron et al., 2006).

In 2007, The European Society of Cardiology Working Group on Myocardial and pericardial Diseases proposed an update of the existing classification scheme defining cardio-

☐ Chapter (1): Dilated Cardiomyopathy ✓

myopathy as a myocardial disorder in which the heart muscle is structurally and functionally abnormal, in the absence of coronary artery disease, hypertension, valvular disease and congenital heart disease sufficient to cause the observed myocardial abnormality (Elliot et al., 2008).

Cardiomyopathies are grouped into specific morphological and functional phenotypes, each phenotype is then sub-classified into familial and non-familial. The most important principle underlying this proposed classification system is its relevance to everyday clinical practice. The division of cardiomyopathies into familial and non–Familial forms is designed to raise awareness of genetic disease as a cause of heart muscle dysfunction and to provide a logical framework on which to base further investigations (*Elliot et al.*, 2008).

Dilated Cardiomyopathy (DCM):

☒ Definition:

The WHO defined dilated cardiomyopathy as myocardial disease characterized by dilatation and impaired contraction of the left ventricle or both left and right ventricles. It may be idiopathic, familial/genetic, viral and/or immune, alcoholic/toxic, or associated with recognized cardiovascular disease in which the degree of myocardial dysfunction is not explained by the abnormal loading conditions or the extent of ischemic damage. The histologic

findings are frequently nonspecific. Presentation is usually with heart failure which is often progressive, arrhythmias, thromboembolism, and sudden death are common and may occur at any stage (*Richardson et al.*, 1996).

☒ Diagnostic criteria:

Mestroni et al. in *1999* identified the diagnostic criteria of dilated cardiomyopathy as left ventricular ejection fraction <0.45 (>2SD) and/or fractional shortening <25% (>2SD) as evaluated by echocardiography, radionuclide scanning or angiography and left ventricular end-diastolic diameter >117% of the predicted value corrected for age and body surface area, which corresponds to 2SD of the predicted normal limit +5%. These findings must be found in absence of:

- 1. Systemic arterial hypertension (>160/100 mmHg documented and confirmed at repeated measurements and/or evidence of target-organ disease).
- Coronary heart disease (obstruction >50% of the diameter in a major branch).
- 3. History of chronic excess alcohol consumption, remission of heart failure after 6 months of abstinence.
- 4. Clinical, sustained and rapid supraventricular arrhythmias
- 5. Systemic diseases.
- 6. Pericardial diseases such as constrictive pericarditis.